You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Epilepsy Treatment: Getting It Right the First Time for Women of Child Bearing Potential

  • Authors: Chairperson: Martha Morrell, MD; Faculty: James Morrow, MD; Gus Baker, MSc, PhD, FBPsS, CClinPsychol; Joyce Cramer, MS
  • THIS ACTIVITY HAS EXPIRED
Start Activity


Target Audience and Goal Statement

This activity has been designed to meet the educational needs of physicians involved in the management of patients with epilepsy.

Upon completion of this activity, participants will be able to:

  1. Discuss the effects of antiepileptic drugs (AED) on reproductive and metabolic health for women in the child-bearing years
  2. Describe emerging data from pregnancy registries related to selecting an AED for women with child-bearing potential
  3. Compare various AEDs on factors such as reproductive endocrine dysfunction and foetal morphological and neurodevelopmental abnormalities.


Author(s)

  • Gus Baker, MSc, PhD, FBPsS, CClinPsychol

    University of Liverpool, Liverpool, UK

    Disclosures

    Disclosure: Grants/Research Support: GlaxoSmithKline, Sanofi Synthelabo, UCB Pharma; Honoraria: GlaxoSmithKline, Pfizer, Inc., Sanofi Synthelabo, UCB Pharma.

  • Joyce Cramer, MS

    Yale University School of Medicine, New Haven, USA

    Disclosures

    Disclosure: Consultant: Abbott Laboratories, GlaxoSmithKline, Novartis Pharmaceuticals, Pfizer, Inc., UCB Pharma.

  • Martha Morrell, MD

    Clinical Professor of Neurology, Stanford University Medical School, Stanford Medical Center, Stanford, CA

    Disclosures

    Disclosure: Grants/Research Support: Abbott Laboratories, Cyberonics, GlaxoSmithKline, Novartis Pharmaceuticals, Ortho-McNeil; Consultant: GlaxoSmithKline, Ortho-McNeil, UCB Pharma.

  • James Morrow, MD

    Royal Victoria Hospital, Belfast, Northern Ireland

    Disclosures

    Disclosure: Professor Morrow received an honorarium from GlaxoSmithKline for his presentation at the live event from which this CME program is based.


Accreditation Statements

    For Physicians

  • This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME). The Postgraduate Institute for Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Postgraduate Institute for Medicine designates this educational activity for a maximum of 2.0 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

The credit that you receive is based on your user profile.

CME

Epilepsy Treatment: Getting It Right the First Time for Women of Child Bearing Potential

Authors: Chairperson: Martha Morrell, MD; Faculty: James Morrow, MD; Gus Baker, MSc, PhD, FBPsS, CClinPsychol; Joyce Cramer, MSFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

processing....

Welcome and Introduction, Presented by Martha Morrell, MD

Introduction: Pharmacologic Control of Seizures

  • I would like to welcome you to this program, "Getting It Right the First Time, for Women of Childbearing Potential."

  • Welcome and Introduction

    Slide 1.

    Welcome and Introduction

    (Enlarge Slide)
  • We are in a fortunate situation now. There are a host of antiepileptic drugs that permit us to become more sophisticated in the care of persons with epilepsy. We think first of seizure control; we think of efficacy. Now, we can go beyond that and talk about tolerability -- both acute tolerability, as it manifests as the drug-related side effects and adverse events, but also, I would suggest, long-term tolerability, or maintenance of long-term health. Finally, we have to appreciate that, for many women with epilepsy -- a disorder that affects individuals for years and often through the reproductive life -- the concerns about maintaining health of the unborn child also are legitimate and quite pressing. That leads us to the concept of epilepsy care -- selecting the therapy that is going to provide the most effectiveness (defined as efficacy, as its ability to treat that patient's seizures), but also tolerability, maintenance of overall health, and safety -- safety to the patient with epilepsy, the woman with epilepsy, and also to her possible progeny.

  • Effective Seizure Control

    Slide 2.

    Effective Seizure Control

    (Enlarge Slide)
  • If we look at the newer antiepileptic drugs and their approval as add-on therapy, we find that we have widespread efficacy, demonstrated in simple and complex partial seizures, as well as in primary and secondary generalized seizures. For the individual with localization-related epilepsy, or partial-onset epilepsy, we find that both the older and the newer antiepileptic drugs have proven effectiveness as add-on therapy. When we look at the generalized-onset seizures (both absence and myoclonic seizures), we see some selectiveness, in terms of efficacy, with those medications approved as add-on therapy for these indications -- including valproate, lamotrigine, and topiramate, with levetiracetam showing some clinical suggestion of effectiveness, but not yet receiving approval. Many of us have moved away from treating with multiple antiepileptic drugs. So, we are especially concerned about the effectiveness of these medications as monotherapy.

  • Approved Use of AEDs as Adjunct Therapy

    Slide 3.

    Approved Use of AEDs as Adjunct Therapy

    (Enlarge Slide)
  • If we look at the newer antiepileptic drugs, 2 of the newer agents -- lamotrigine and topiramate -- have been approved for both partial-onset and generalized-onset seizures, whereas gabapentin and levetiracetam have yet to show effectiveness or receive approval. If we think of effectiveness as including broad spectrum, there are some considerations that would lead us toward some vs others of the newer antiepileptic drugs.

  • Approved Use of New Generation AEDs as Monotherapy

    Slide 4.

    Approved Use of New Generation AEDs as Monotherapy

    (Enlarge Slide)

Issues Affecting Women Particularly

  • As we think of issues relevant for women, we tend to think of issues as being relevant to particular ages. In other words, those concerns that are most pressing for the child or teenager with epilepsy; those that are of most concern for women of childbearing potential, or women in their reproductive years; and those of concern to women at the end of their reproductive life, or in the postmenopausal phase. I would suggest that there is a great deal of overlap. For the adolescent and woman of childbearing potential, we may be concerned with contraceptive efficacy; for the woman of childbearing potential, we may be concerned about metabolic and endocrine health -- but that concern also is relevant to the adolescent, and to the woman in the perimenopausal years. We think about bone disease as being relevant, almost entirely, to women after reproductive age or in menopausal age; but we will show data suggesting that this is a concern that spans all phases of the life span. We will hear about mood and depression, issues not only for the woman of childbearing potential, but for the child, the adolescent, and the postmenopausal woman.

  • Women of Childbearing Potential

    Slide 5.

    Women of Childbearing Potential

    (Enlarge Slide)
  • If we think about the goals in treating women with epilepsy, we can develop an algorithm, with the first node, or the first decision point, being: which medication is going to be most likely to protect my patient from seizures? But, given that, there are special concerns if that patient is a child or an adolescent. If it is a reproductive-age woman, we are particularly concerned about maintaining normal physiology -- maintaining metabolic and endocrine health -- leading to normal fertility and normal sexual drive. We want to avoid unplanned pregnancies, by ensuring that our choice of contraception is going to be effective. We also want, in the woman planning to become pregnant, to ensure that her pregnancy outcome is successful. For all women and men with epilepsy, we want to ensure that this brain disorder is not accompanied by depression or other affective disorders, and that the individual is able to think clearly and maintain optimal intellectual functioning. Finally, I would suggest -- again at all ages and for women, as well as men -- that maintaining normal bone health is essential and an area where we have data suggesting that this patient population may be at risk.

  • Goals in Treating Women With Epilepsy

    Slide 6.

    Goals in Treating Women With Epilepsy

    (Enlarge Slide)
  • We will get it right about 50% of the time. In other words, no matter what antiepileptic medication we select for an individual with partial-onset seizures, from among those medications shown to be effective for generalized-onset seizures, about 50% of persons will maintain success -- will have a drug that is effective the first time around. This has been demonstrated particularly by the research of Drs. Kwan and Brodie. When we find a medication that is effective it is very desirable, because our patients are going to be on this medication for years or even a lifetime. But if we do not get it right, if the medication is not a perfect choice -- if the patient is seizure-free, but if short- or long-term health is in any way compromised by that medication -- then we find that it may be difficult to change. Once somebody is seizure-free, even with side effects, it is very difficult to convince that patient to undergo a medication changeover, because of the risks of breakthrough seizures and how that might compromise employment or driving. That makes it imperative that we think about, not only the medications most likely to achieve seizure control, but the medications that are going to maintain health over the long term. That is going to lead us to the best shot at finding a medication that achieves effectiveness the first time around.

  • Antiepileptic Drugs: Getting It Right First Time

    Slide 7.

    Antiepileptic Drugs: Getting It Right First Time

    (Enlarge Slide)